August 2012
-
Inhaler monitoring company Adherium has submitted a 510(k) application for a new Hailie sensor designed to work with the Symbicort MDI the company announced. The company recently rejected a takeover bid from another Australian asthma… Read more . . .
-
Noveome Biotherapeutics has signed a commercial license agreement for the use of SipNose’s intranasal Cribriform Targeted Device (CT6) for delivery of its ST266 secretome for the treatment of ophthalmological and CNS conditions the companies said.… Read more . . .
-
According to Lannett, the FDA has set a GDUFA goal date of January 31, 2022 for completion of its review of the ANDA for Respirent’s generic version of Advair Diskus fluticasone propionate / salmeterol DPI… Read more . . .
-
AIM ImmunoTech said that it has extended a 2020 agreement with Shenzhen Smoore Technology related to development of an inhaled version of its Ampligen rintatolimod for the treatment of COVID-19. The agreement with Smoore is… Read more . . .
-
The EMA’s COVID-19 task force has said “that there is currently insufficient evidence that inhaled corticosteroids are beneficial for people with COVID-19.” In addition, the task force said that “it could not exclude the possibility… Read more . . .
-
The UK Ministry of Healthcare Products Regulatory Agency (MHRA) announced that it has approved an application from Aventis Pharma (Sanofi) to reclassify Nasacort Allergy Relief triamcinolone acetonide nasal spray for the treatment of allergic rhinitis in… Read more . . .
-
According to North Carolina-based startup Inhalon Biopharma, the US Army Medical Research & Development Command (USAMRDC) has awarded the company a contract worth $7 million for a Phase 1/2a study of its IN-006 inhaled neutralizing… Read more . . .
-
The Swedish Medical Product Agency (Läkemedelsverket) has approved an application from Inhalation Sciences (ISAB) for a clinical trial of its PreciseInhale aerosol generation system, the company said. ISAB expects to initiate the trial in June… Read more . . .
-
VistaGen Therapeutics has announced the initiation of the PALISADE-1 Phase 3 clinical trial of PH94B aloradine nasal spray for the treatment of social anxiety disorder (SAD). PH94B was granted Fast Track designation for that indication… Read more . . .
-
A newly formed company called Murano Bidco, which is controlled by the Carlyle Group, has agreed to pay approximately £958 million to acquire inhalation CDMO Vectura, the companies have announced. According to the announcement, Bidco… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.